| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Goldfinch Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $190.22M | Series B | 6/30/2020 | $105.91M | $252.06M | $1.18 | Eventide Asset Management, Wellington Management Company, Ally Bridge Group, BlackRock, Casdin Capital, Irving Investors, Gilead Sciences, Yonjin Capital, Schroeder Adveq | ||||
 | Homeward Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $100.4M | Series B-1 | 8/20/2026 | $30.4M | $398.59M | $12.85 | Undisclosed Investors | ||||
 | IntelyCare | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $237.55M | Series D | 10/29/2026 | $6M | $51.7M | $0.54 | -- | ||||
 | LifeMine | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $522.71M | Series E | 8/6/2026 | $150.54M | $469.78M | $0.78 | Milky Way Investments, Bezos Expeditions, Gates Frontier, RA Capital Management, GV, LoLa Capital Partners, GSK, Invus, ARCH Venture Partners | ||||
 | Nalu | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $331.77M | Series E | 10/9/2024 | $115.06M | $382.56M | $4.85 | Novo Holdings, Gilde Healthcare, MVM Partners, Endeavour Vision, Decheng Capital, Longitude Capital, Advent Life Sciences, Pura Vida, Aperture Venture Partners, B Capital | ||||
 | Neomorph | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $208.74M | Series B | 4/13/2026 | $114.04M | $340.23M | $1.32 | Deerfield Management, Regeneron Ventures, Longwood Fund, Alexandria Venture Investments, Binney Street Capital | ||||
 | NextPoint | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $196.84M | Series B | 7/30/2026 | $156.21M | $356.79M | $6.00 | Catalio Capital, MPM BioImpact, Leaps by Bayer, Sanofi Ventures, Invus, Sixty Degree Capital, Binney Street Capital, Gordon Freeman, Arkin Capital, WTT Investment, PagodaTree Partners | ||||
 | NOCD | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $85.23M | Series C-1 | 1/31/2023 | $8.33M | $263.2M | $20.22 | Cigna Ventures, 7wireVentures, Longitude Capital, Kaiser Permanente, F-Prime Capital, Eight Roads Capital, Health Enterprise Partners | ||||
 | OrsoBio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $166.63M | Series B | 9/6/2024 | $67M | $316.32M | $0.71 | Ascenta Capital, Woodline Partners, Samsara Biocapital, Longitude Capital, Enavate Sciences, NuevaBio, Eli Lilly and Company | ||||
 | Pearl Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $125.27M | Series C | 7/8/2026 | $50M | $284.96M | $0.67 | Andreessen Horowitz, Viking Global Investors, AlleyCorp, Ulysses Capital, Gaingels, Alumni Ventures | ||||
 | Pelago | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $478.23M | Series C | 3/28/2024 | $58M | $349.85M | $17.55 | Atomico, Kinnevik AB, Octopus Ventures, Y Combinator, Eight Roads, GreyMatter Capital | ||||
 | Proclara Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $112.79M | Series F | 11/7/2018 | $6.92M | $310.98M | $0.90 | Undisclosed Investors | ||||
 | Relievant Medsystems | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $247.66M | Series G | 3/17/2023 | $50M | $361.21M | $0.11 | Undisclosed Investors | ||||
 | Sapience Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $63.88M | Series B | 5/31/2022 | $28.25M | $289.73M | $3.60 | NexPoint, Bristol Myers Squibb, Eshelman Ventures, Kingdon Capital | ||||
 | SetPoint Medical | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $302.51M | Series D | 10/28/2025 | $115.5M | $471.52M | $1.51 | Elevage Medical Technologies, Ally Bridge Group, Northwell Health, SPRIG Equity, Norwest Venture Partners, New Enterprise Associates, Viking Global Investors, Action Potential Venture Capital, Abbott, Boston Scientific, Euclidean Capital, Richard King Mellon Foundation, Morgenthaler Ventures, ShangBay Capital, Ascendum Capital, Catalio Capital Management, Gilmartin Capital, Midas Capital | ||||
 | Third Pole Therapeutics | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $110.79M | Series B-2 | 3/13/2025 | $11.97M | $243.11M | $36.51 | Starpath Ventures, Acord Campus Taiwan | ||||
 | TigerConnect | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $127.92M | Series D-1 | 10/8/2020 | $41.5M | $366.32M | $4.20 | HealthQuest Capital, New Leaf Ventures, Montreux Growth Partners, Norwest Venture Partners, Invus, Industry Ventures | ||||
 | Tome Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $245.57M | Series B | 12/12/2023 | $150M | $435.54M | $3.03 | Andreessen Horowitz, ARCH Venture Partners, GV, Longwood Fund, Polaris Partners, Bruker Corporation, FUJIFILM Corporation, Alexandria Venture Investments | ||||
 | Vanqua Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $149.15M | Series B | 7/12/2024 | $130M | $333.4M | $4.06 | Omega Funds, OrbiMed, Citadel, Avoro Ventures, Casdin Capital, Pontifax, Eli Lilly and Company, Logos Capital, Osage University Partners | ||||
 | Zephyr AI | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $129.71M | Series A | 3/13/2024 | $69.01M | $482.26M | $17.34 | Revolution Growth, Eli Lilly and Company, Jeff Skoll, EPIQ Capital Group | ||||
 | Airway Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $113.09M | Series E-2 | 8/25/2026 | $24M | $299.51M | $1.72 | Cincinnati Children's Hospital | ||||
 | Akili | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $275.08M | Series D | 5/26/2021 | $151.68M | $452.34M | $8.43 | Neuberger Berman Funds, Polaris Partners, Mirae Assets, Shionogi & Co LTD, New Leaf Venture Partners, Dave Baszucki, QUAD Investment Management, Ladera Venture Partners, Temasek, Baillie Gifford, JAZZ Venture Partners, Evidity Health Capital, Omidyar Technology Ventures, Fearless Ventures, Amgen Ventures, M Ventures | ||||
 | Alleviant Medical | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $182.73M | Series 2 | 1/14/2025 | $91.4M | $258.67M | $1.28 | Gilde Healthcare, Omega Funds, S3 Ventures, RiverVest Venture Partners, Vensana Capital, Longview Ventures, Gilmartin Capital, TMC Corporation | ||||
 | Allotera Therapeutics | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $322.92M | Series C | 7/23/2026 | $83.2M | $291.45M | $1.77 | Fidelity, RiverVest Venture Partners, Lightchain Capital, LYZZ Capital, Abingworth, Intermediate Capital Group, Tybourne Capital Management, Aisling Capital Management, BioGenerator Ventures, Sands Capital, Alexandria Venture Investments, Velosity Capital, Falcon Edge Capital | ||||